Key Takeaways
- Florida discharge plans must survive the first 28 days after withdrawal management, when tolerance has dropped and mortality risk is concentrated, especially for detoxification exits 13.
- A defensible chart shows a named receiving provider with a scheduled date, medication continuity, warm-handoff evidence, naloxone with training, and documented MOUD continuation or informed refusal for opioid patients 3, 10.
- Since February 16, 2026, a single TPO consent under the updated Part 2 rule can cover the full referral network, but class language, BAAs, and redisclosure posture with each Florida partner still need active cleanup 9.
- Alcohol and stimulant pathways need substance-specific handoffs and higher-touch post-discharge contact, because linkage odds fall sharply without a bridge medication doing the appointment-forcing work 14, 4.
The 28-Day Window That Reframes Discharge Work
You already know the paperwork side of discharge. What deserves more room in your workflow reviews is the biology of the transition itself. When a patient leaves withdrawal management, tolerance has dropped, structure disappears, and the medication that was holding risk down often stops. That is the window your aftercare plan has to survive.
The clearest picture comes from pooled mortality data on opioid substitution treatment. All-cause mortality was 11.3 per 1,000 person-years while patients were in methadone treatment and 36.1 out of it. Overdose-specific mortality was 2.6 in treatment and 12.7 out 7. Those figures pre-date the fentanyl era, so today’s absolute risk is likely worse, not better. A Texas record-linkage study of treatment discharges found drug-related mortality concentrated in the first 28 days post-discharge, with detoxification episodes carrying higher risk than outpatient exits 13. That is the window your handoffs, callbacks, and bridge prescriptions are actually working against.
That framing carries through every section that follows.
What Florida Discharge Plans Actually Have to Prove
You are working inside a stack of overlapping expectations: state licensing, federal SUD confidentiality, Medicaid managed care contract language, ASAM continued-service criteria, and your own accreditation body. When an auditor or a peer reviewer pulls a chart, the plan has to prove specific things happened, not just that boxes were checked.
At a minimum, a defensible Florida discharge plan documents:
- a named receiving provider with a scheduled appointment on a specific date,
- the medications the patient is leaving with and how the next prescription will be filled,
- a working phone number the patient can reach and a working phone number staff will use for follow-up,
- transportation to the first appointment,
- housing status at discharge,
- naloxone provided with training when opioids are in the picture, and
- a mutually agreed set of referrals that the patient actually signed off on rather than passively received 3.
For patients with opioid use disorder, CDC guidance is direct that detoxification alone without medication for OUD is not recommended because of elevated risk of resumed use and overdose death, so your plan needs to document either MOUD continuation, an active offer with informed refusal, or a clinical contraindication 10.
Two pieces are easy to miss and expensive to defend without. The first is evidence of a warm handoff rather than a phone number on a discharge sheet—who called whom, when, and what was confirmed. The second is documented overdose-prevention education paired with naloxone distribution, which SAMHSA treats as a routine transition-planning element whenever care changes significantly, including discharge from withdrawal management 3.
If your chart cannot show those elements, the plan will not hold up as a clinical safety intervention, regardless of how complete the intake paperwork looked.
Part 2 After February 16, 2026: Consent Workflow for Referral Coordinators
Single Consent for TPO and What It Changes at Intake
The 2024 Part 2 final rule became effective April 16, 2024, and compliance was required by February 16, 2026 2. That date has passed, so your intake packet, EHR consent screens, and referral scripts should already reflect the change. If they don’t, that is the first thing to fix this quarter.
The operational shift you care about most: a patient can now sign a single written consent authorizing all future uses and disclosures for treatment, payment, and health-care operations, rather than a separate consent for every downstream provider 9. For a Florida detox admitting a patient at 2 a.m. who will need a MAT clinic, a primary care handoff, a housing referral, a Medicaid managed care plan, and possibly a probation officer contact within 10 days, that is a real workflow improvement. You can execute one consent that covers the network your case managers actually use.
But the elements haven’t gotten looser. The written consent still has to identify the patient and the person or class of persons authorized to make the use or disclosure, and it can be paper or electronic 1. If you’re using a class-based description like “any licensed SUD treatment provider the patient is referred to,” the class has to be defined clearly enough that a downstream auditor can tell who was covered. Vague single-consent language will not survive review just because the rule technically permits broader scope. Rewrite your template with your compliance officer and get it signed at intake, not at discharge when the patient is packing.
Redisclosure, Segmented Records, and Business Associate Cleanup
The redisclosure rules are where coordinators still get tripped up. Under the 2024 rule, certain HIPAA-covered recipients can redisclose Part 2 records under HIPAA rather than under the tighter Part 2 standard 9. That sounds like relief, and in most treatment coordination scenarios it is. It also means the receiving MAT clinic, primary care office, or hospital in your referral network needs to know whether they are a HIPAA-covered entity and how their own notice of privacy practices handles the SUD segment. Ask. Do not assume.
Heightened protections still apply in civil, criminal, administrative, and legislative proceedings 1. If a patient’s record moves to a downstream Florida provider and then gets subpoenaed, the Part 2 restrictions travel with it. Your ROI form should say so in plain language, and your partners should have segmentation capability in their EHR to flag records that originated with your program.
The business associate cleanup is the least glamorous piece and the one most likely to fail an audit. Every vendor that touches Part 2 data on your behalf—your EHR, your e-fax, your care coordination platform, your outbound call service, your billing clearinghouse—needs a BAA that reflects the 2024 rule’s language on Part 2 redisclosure, patient rights, and breach notification 9. Pull your vendor list, cross-check the BAA dates, and reissue anything signed before April 2024. That is a one-afternoon project that closes a real exposure.
Substance-Specific Aftercare Pathways
Opioid Pathway: Bridge Medication and OTP Notification
The opioid pathway is the one where the evidence for facilitated linkage is loudest, and the one where a weak handoff is most likely to end in an obituary. CDC is direct: detoxification alone without medication for OUD is not recommended because of the elevated risk of resumed use, overdose, and overdose death 10. That single line should be the governing rule at the top of your opioid discharge protocol. Every opioid patient leaves with MOUD continuing, an active offer with informed refusal documented, or a specific clinical contraindication in the chart.
The strongest trial evidence you have to point partners toward comes from the Liebschutz randomized trial of hospitalized opioid-dependent patients. Patients randomized to buprenorphine induction, stabilization, and facilitated linkage had a treatment entry rate of 72.2%, compared with 11.9% for those receiving inpatient detoxification alone. At six months, 16.7% of the linkage group was still in buprenorphine treatment versus 3.0% of the detox-only group 12. Those are hospitalized patients, not Florida detox admissions, but the mechanism is the same: bridge medication plus a scheduled receiving appointment outperforms a phone number every time.
Build the pathway around three moves:
- Start or continue MOUD in the facility and send the patient out with a bridge prescription or induction plan that reaches the first outpatient visit.
- If the patient has an existing OTP relationship, notify that program at admission and again at discharge with the medications received and prescribed at exit, per TIP 63 11.
- Provide naloxone with training and confirmed crisis numbers as a routine transition-planning element, not an add-on 3.
If any of those three is missing when you audit a chart, treat it as a defect, not a preference.
Alcohol and Stimulant Pathways: Why Linkage Odds Drop
Here is where a lot of Florida programs quietly underperform: they run one workflow for every discharge, and it is a workflow designed around opioids. The linkage data tells you why that fails. A Vancouver study of 264 detoxification encounters found that 66% linked to community SUD treatment overall, but the odds varied sharply by substance. Compared with opioid-related detox, stimulant-related detox had an adjusted odds ratio of 0.23 for linkage, and alcohol-related detox had an adjusted odds ratio of 0.17 14. That is a Vancouver dataset, not a Florida one, and the receiving-provider ecosystem differs. The operational lesson still applies: without a substance-specific handoff design, your alcohol and stimulant patients are far less likely to make it into continuing care than your opioid patients, even when the same referral list goes home in the same folder.
Part of the reason is structural. There is no bridge medication for stimulant use disorder with the same linkage pull as buprenorphine. Naltrexone and acamprosate exist for alcohol, and both belong in the discharge conversation, but neither carries the same appointment-forcing logic as an OTP dose schedule. So the linkage work has to do more of the lifting.
For alcohol, build the pathway around a scheduled outpatient appointment within seven days, a documented conversation about naltrexone or acamprosate with a prescriber identified by name, and a mutual-help or IOP connection the patient actually agreed to 3, 4. For stimulants, lean harder on peer support, contingency-management-capable programs where they exist in your county, and higher-touch post-discharge contact—a 48-hour call is not optional, it is the intervention 4. And for both, name the receiving clinician when you make the handoff. “We referred them to the MAT clinic” is not a handoff. “Dr. Ruiz is expecting them Thursday at 10” is.
Pre-Discharge vs Post-Discharge Tactics: A Coordinator’s Audit Table
The 2023 scoping review that most people cite when they talk about SUD care transitions mapped 10 concrete tactics, five that happen before the patient walks out and five that happen after 4. It is worth pulling that structure onto a single page, because when you audit your own workflow or a partner’s, you want to see which side of the discharge door is doing the work. Programs that lean entirely on pre-discharge paperwork and assume the patient will show up tend to lose alcohol and stimulant patients in particular, where linkage odds are already lower 14.
Here is the split, adapted for a Florida coordinator’s audit:
| Phase | Tactic | What a defensible chart shows | Substance emphasis |
|---|---|---|---|
| Pre-discharge | Discuss continuing-care options with the patient | Documented conversation, patient preferences noted, mutual agreement on referral 3 | All substances |
| Pre-discharge | Schedule the first outpatient appointment | Named provider, specific date and time confirmed with receiving office | All; within 7 days for alcohol and stimulant 4, 14 |
| Pre-discharge | Provide a curated provider list, not a directory | Short list matched to insurance, geography, substance, and language | All substances |
| Pre-discharge | Send an electronic referral with clinical summary | Referral transmitted under valid Part 2 consent, receipt confirmed 1 | All substances |
| Pre-discharge | Facilitated linkage before discharge (introduction to receiving clinician) | Warm introduction documented; ideally in person or by video before the patient leaves | Highest yield for opioids 12 |
| Post-discharge | Bridge prescription to the first outpatient visit | Prescription written, pharmacy confirmed, gap closed | Opioid (MOUD), alcohol (naltrexone or acamprosate) 10, 11 |
| Post-discharge | Transportation to the first appointment | Ride arranged, confirmed the morning of, backup plan documented | All substances |
| Post-discharge | Follow-up calls or texts on a defined cadence | 48-hour, 7-day, and 14-day contacts logged with outcome | Highest touch for stimulant 4, 14 |
| Post-discharge | Care navigation or case management | Named navigator assigned, caseload documented, escalation path clear | All substances |
| Post-discharge | Peer support connection | Peer contact made within 72 hours, ongoing contact plan in writing | Strongest lever for stimulant; useful across all 4 |
Use this as your audit worksheet. If a chart shows five pre-discharge tactics and zero post-discharge tactics, you are looking at a program that hands off paper and hopes. If a chart shows the reverse, you are looking at a program that chases patients after the fact instead of teeing up a real appointment. You want both columns populated, and you want the substance-emphasis column reflected in how the plan was actually built rather than filed as an afterthought.
The First 28 Days: A Contact Cadence That Holds
Coordinating this part of the work is genuinely hard, and it deserves credit. You are asking a patient who just finished withdrawal to answer their phone, show up to an appointment, refill a prescription, and stay reachable during the four weeks their body is most vulnerable. A cadence that holds is what makes the difference between a plan on paper and a plan that survives contact with real life.
Build the cadence around three anchor points, and document each one the same way you would document a vital sign.
The 48-hour call is your first proof of life. Someone from your team—ideally the case manager the patient met on the unit, not an unfamiliar voice—calls within two days of discharge. You confirm the patient is home, the bridge medication is in hand, the first appointment is still on the calendar, and naloxone is accessible. If you cannot reach the patient, the call goes to the emergency contact on the consent, and the attempt is logged. Two failed contacts inside 72 hours should trigger escalation to the receiving provider and the peer support connection, not a note that says “unable to reach.”
The 7-day check-in confirms the first appointment happened. Not that it was scheduled—that it happened. Your workflow needs a closed-loop confirmation from the receiving MAT clinic, outpatient program, or prescriber, which is exactly the kind of routine care-coordination communication the single TPO consent under the 2024 Part 2 rule was designed to make workable 9. If the appointment was missed, this is the moment to re-engage, not the moment to close the referral.
The 14-day contact tests medication continuity and appointment two. Was the prescription refilled? Is the patient still connected to the receiving provider? Is transportation still working? SAMHSA treats overdose-prevention education, naloxone, crisis numbers, and mutually agreed follow-up as routine transition-planning elements, and the 14-day contact is where you verify those safeguards are still in place rather than assuming they carried over from discharge day 3.
A fourth contact around day 28 closes the highest-risk window and hands the patient cleanly to their continuing-care team. The Texas record-linkage study that anchored the risk framing earlier in this piece found mortality concentrated in exactly this 0–28 day span after discharge, which is why the cadence ends here rather than at two weeks 13.
Auditing Your Referral Partners
Your discharge plan is only as strong as the receiving end. When you audit a MAT clinic, outpatient program, or sober-living referral, you are checking whether they can actually catch what you throw. Build the audit around six questions you ask before you send another patient.
- Can they take a warm handoff by phone or video before the patient leaves your unit, and how fast? A 24-hour answer is workable; a five-day callback is not.
- Do they accept your Part 2 consent language and redisclose under HIPAA where permitted, or does their intake team still ask for a fresh authorization that delays the first appointment 9?
- Can they induct or continue buprenorphine, dose methadone in coordination with an OTP, and prescribe naltrexone or acamprosate without a two-week wait 10, 11?
- What is their no-show re-engagement protocol—do they call the patient back, or do they close the referral?
- Ask for their 30-day retention rate for patients admitted through detox referrals. If they cannot produce a number, that is the finding.
- Confirm they will send you closed-loop confirmation that the first appointment happened, which is the data point your 7-day contact depends on.
Document each partner’s answers in a shared file your case managers can actually pull up at 2 a.m.
If You Coordinate Across Multiple Florida Detox Sites
A quick scope shift: if you are running aftercare coordination across two or more Florida sites—say a Fort Lauderdale unit, an Orlando unit, and a Palm Beach unit feeding into overlapping MAT clinics and Medicaid managed care plans—the operational problem changes. You are no longer auditing one workflow. You are trying to keep three from drifting apart.
Three things are worth standardizing at the network level, even if you leave clinical judgment local:
- One Part 2 consent template across every site, reviewed against the 2024 final rule and re-signed by every business associate you share it with 9. When a patient moves between your sites or from one site to a shared referral partner, the receiving intake team should recognize the form on sight.
- One contact-cadence spec: the same 48-hour, 7-day, 14-day, and 28-day check-ins, owned by a named case manager, logged in the same fields in the same system. That is the only way you can compare no-show rates and re-engagement outcomes across sites and actually learn something.
- One shared referral-partner file with the six audit questions from the previous section answered per partner, per site. If your Orlando team knows a MAT clinic returns closed-loop confirmations within 24 hours and your Palm Beach team does not, that is a coordination failure, not a partner problem.
Standardize the workflow. Let the clinicians tailor the care.
Frequently Asked Questions
Does the 2024 Part 2 final rule let us share SUD records with any downstream Florida provider once we have consent?
Not quite. A single written consent can now authorize all future uses and disclosures for treatment, payment, and health-care operations, which covers most of your referral network 9. The consent still has to identify the patient and the person or class of persons authorized to receive the disclosure, and heightened protections still apply in legal proceedings 1. Define your class language carefully and confirm each partner’s redisclosure posture before you assume records can move freely.
What has to be documented in a Florida detox discharge plan to hold up under audit?
Your chart needs a named receiving provider with a specific appointment date, the medications the patient leaves with and how the next prescription gets filled, working phone numbers in both directions, transportation to the first visit, housing status, naloxone with training when opioids are involved, and mutually agreed referrals the patient actually signed off on 3. For opioid patients, document MOUD continuation, an active offer with informed refusal, or a clinical contraindication 10. Warm-handoff evidence matters most.
Why do alcohol and stimulant discharges need a different aftercare workflow than opioid discharges?
Linkage odds drop sharply without a bridge medication doing the appointment-forcing work. A Vancouver study of 264 detox encounters found stimulant-related detox had an adjusted odds ratio of 0.23 for community linkage compared with opioid-related detox, and alcohol-related detox had an AOR of 0.17 14. That is not a Florida dataset, but the operational lesson holds: alcohol pathways need a scheduled naltrexone or acamprosate conversation and a seven-day appointment, and stimulant pathways need higher-touch post-discharge contact and peer support 4.
What contact cadence should we build for the first 28 days after discharge?
Four anchor contacts, each documented like a vital sign. A 48-hour call confirms the patient is home, medication is in hand, and the first appointment is on the calendar. A 7-day check-in confirms that appointment actually happened via closed-loop confirmation from the receiving provider. A 14-day contact tests prescription refills and transportation. A 28-day contact closes the highest-risk window, which record-linkage evidence identifies as the concentrated post-discharge mortality span 13. Put each contact on a task queue with a named owner.
How do we notify a patient’s opioid treatment program at admission and discharge?
TIP 63 gives you the operational script. Notify the patient’s OTP at admission, share what medications the patient received during your episode, and notify again at discharge with the medications prescribed at exit and any missed visits during the stay 11. Do this under the single TPO consent your intake team should already have on file after the 2024 Part 2 rule 9. Confirm the OTP’s next dose date before the patient leaves your unit, not after.
What should we look for when auditing a referral partner’s ability to accept a warm handoff?
Six questions. Can they take a phone or video introduction within 24 hours? Do they accept your Part 2 consent and redisclose under HIPAA where permitted 9? Can they induct or continue buprenorphine, coordinate methadone with an OTP, and prescribe naltrexone or acamprosate without a two-week wait 10, 11? What is their no-show re-engagement protocol? What is their 30-day retention rate for detox referrals? Will they send closed-loop confirmation that the first appointment happened? Document each answer.
References
- 42 CFR Part 2 — Confidentiality of Substance Use Disorder Patient Records. https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-2
- Understanding Confidentiality of Substance Use Disorder (SUD) Patient Records. https://www.hhs.gov/hipaa/part-2/index.html
- Federal Guidelines for Opioid Treatment Programs. https://library.samhsa.gov/sites/default/files/federal-guidelines-opioid-treatment-pep24-02-011.pdf
- Strategies to support substance use disorder care transitions from acute care to community-based treatment: A scoping review. https://pmc.ncbi.nlm.nih.gov/articles/PMC10621088/
- An evaluation of the association between specific post-overdose care services in emergency departments and subsequent treatment engagement. https://pmc.ncbi.nlm.nih.gov/articles/PMC9833281/
- Non-fatal overdose risk during and after opioid agonist treatment: A primary care cohort study with linked hospitalisation and mortality records. https://pubmed.ncbi.nlm.nih.gov/36034051/
- Mortality risk during and after opioid substitution treatment. https://pubmed.ncbi.nlm.nih.gov/28446428/
- Substance Use Dashboard: Overdoses – FLHealthCHARTS. https://www.flhealthcharts.gov/ChartsDashboards/rdPage.aspx?rdReport=SubstanceUse.Overdose
- Fact Sheet 42 CFR Part 2 Final Rule. https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/fact-sheet-42-cfr-part-2-final-rule/index.html
- Guideline Recommendations and Guiding Principles. https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/recommendations-and-principles.html
- TIP 63: Medications for Opioid Use Disorder. https://library.samhsa.gov/sites/default/files/pep21-02-01-002.pdf
- Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. https://pubmed.ncbi.nlm.nih.gov/25090173/
- Drug-related mortality after discharge from treatment: A record-linkage study of substance abuse clients in Texas, 2006-2012. https://pubmed.ncbi.nlm.nih.gov/31520924/
- Medical Detoxification for Nonopioid Substances Is Associated With Lower Likelihood of Subsequent Linkage to Substance Use Disorder Treatment. https://pubmed.ncbi.nlm.nih.gov/35245917/
